Skip NavigationSkip to Content

NCI at Frederick Scientific Publications Advanced Search

Search

  1. NCI-F Publications

  2. Return to Quick Search
Search
  2. Year Published:

Your search returned 130 results.
User Information
Export Records
  1. 1.   Bioinformatic analysis linking genomic defects to chemosensitivity and mechanism of action
  2. Covell,David
  3. PloS one. 2021, Apr 28; 16(4):
  1. 2.   The metabolic landscape of RAS-driven cancers from biology to therapy
  2. Mukhopadhyay,Suman; Vander Heiden, Matthew G.; McCormick, Frank
  3. Nature Cancer. 2021, Mar; 2(3): 271-283.
  1. 3.   A YAP/FOXM1 axis mediates EMT-associated EGFR inhibitor resistance and increased expression of spindle assembly checkpoint components
  2. Nilsson, Monique B.; Sun, Huiying; Robichaux, Jacqulyne; Pfeifer, Matthias; McDermott, Ultan; Travers, Jon; Diao, Lixia; Xi, Yuanxin; Tong, Pan; Shen, Li; Hofstad, Mia; Kawakami, Masanori; Le, Xiuning; Liu, Xi; Fan, Youhong; Poteete, Alissa; Hu, Limei; Negrao, Marcelo; Tran, Hai; Dmitrovsky, Ethan; Peng, David; Gibbons, Don L.; Wang, Jing; Heymach, John
  3. SCIENCE TRANSLATIONAL MEDICINE. 2020, SEP 2; 12(559): pii: aaz4589.
  1. 4.   Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia
  2. Winn, Blake A; Devkota, Laxman; Kuch, Bunnarack; MacDonough, Matthew T; Strecker, Tracy E; Wang, Yifan; Shi, Zhe; Gerberich, Jeni L; Mondal, Deboprosad; Ramirez, Alejandro J; Hamel,Ernest; Chaplin, David J; Davis, Peter; Mason, Ralph P; Trawick, Mary Lynn; Pinney, Kevin G
  3. Journal of natural products. 2020, APR 24; 83(4): 937-954.
  1. 5.   Review: Precision medicine and driver mutations: Computational methods, functional assays and conformational principles for interpreting cancer drivers
  2. Nussinov,Ruth; Jang,Hyunbum; Tsai,Chung-Jung; Cheng, Feixiong
  3. PLoS computational biology. 2019, Mar; 15(3):
  1. 6.   Design, Synthesis, and Biological Evaluation of 6-Substituted Thieno[3,2-d]pyrimidine Analogues as Dual Epidermal Growth Factor Receptor Kinase and Microtubule Inhibitors
  2. Romagnoli, Romeo; Prencipe, Filippo; Oliva, Paola; Baraldi, Stefania; Baraldi, Pier Giovanni; Schiaffino Ortega, Santiago; Chayah, Mariem; Kimatrai Salvador, Maria; Carlota Lopez-Cara, Luisa; Brancale, Andrea; Ferla, Salvatore; Hamel,Ernest; Ronca, Roberto; Bortolozzi, Roberta; Mariotto, Elena; Mattiuzzo, Elena; Viola, Giampietro
  3. JOURNAL OF MEDICINAL CHEMISTRY. 2019, Feb 14; 62(3): 1274-1290.
  1. 7.   Personal Mutanomes Meet Modern Oncology Drug Discovery and Precision Health
  2. Cheng, Feixiong; Liang, Han; Butte, Atul J.; Eng, Charis; Nussinov, Ruth
  3. Pharmacological reviews. 2019, Jan; 71(1): 1-19.
  1. 8.   Multiple configurations of EGFR exon 20 resistance mutations after first- and third-generation EGFR TKI treatment affect treatment options in NSCLC
  2. Goldberg, Michael E.; Montesion, Meagan; Young, Lauren; Suh, James; Greenbowe, Joel; Kennedy, Mark; Giaccone, Giuseppe; Akerley, Wallace L.; Dowlati, Afshin; Creelan, Benjamin C.; Hicks, James K.; Hesketh, Paul J.; Kelly, Karen L.; Riess, Jonathan W.; Miller, Vincent A.; Stephens, Philip J.; Frampton, Garrett M.; Ali, Siraj; Gregg, Jeffrey P.; Albacker, Lee A.
  3. PLOS ONE. 2018, NOV 27; 13(11):
  1. 9.   LMTK3 confers chemo-resistance in breast cancer
  2. Stebbing, Justin; Shah, Kalpit; Lit, Lei Cheng; Gagliano, Teresa; Ditsiou, Angeliki; Wang, Tingting; Wendler, Franz; Simon, Thomas; Szabo, Krisztina Sara; O'Hanlon, Tim; Dean, Michael; Roslani, April Camilla; Cheah, Swee Hung; Lee, Soo-Chin; Giamas, Georgios
  3. ONCOGENE. 2018, JUN; 37(23): 3113-3130.
  1. 10.   Engaging Anaphase Catastrophe Mechanisms to Eradicate Aneuploid Cancers
  2. Kawakami, Masanori; Mustachio, Lisa Maria; Liu, Xi; Dmitrovsky, Ethan
  3. Molecular Cancer Therapeutics. 2018, Apr; 17(4): 724-731.
  1. 11.   Phase I Trial of M7824 (MSB0011359C), a Bifunctional Fusion Protein Targeting PD-L1 and TGF beta, in Advanced Solid Tumors
  2. Strauss, Julius; Heery, Christopher R.; Schlom, Jeffrey; Madan, Ravi A.; Cao, Liang; Kang, Zhigang; Lamping, Elizabeth; Marte, Jennifer L.; Donahue, Renee N.; Grenga, Italia; Cordes, Lisa; Christensen, Olaf; Mahnke, Lisa; Helwig, Christoph; Gulley, James L.
  3. Clinical Cancer Research. 2018, Mar 15; 24(6): 1287-1295.
  1. 12.   A New View of Pathway-Driven Drug Resistance in Tumor Proliferation
  2. Nussinov, Ruth; Tsai, Chung-Jung; Jang, Hyunbum
  3. TRENDS IN PHARMACOLOGICAL SCIENCES. 2017, May; 38(5): 427-437.
  1. 13.   Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy
  2. Logue, J. S.; Morrison, D. K.
  3. Genes & Development. 2012, Apr; 26(7): 641-650.
  1. 14.   Single-Cell Exome Sequencing Reveals Single-Nucleotide Mutation Characteristics of a Kidney Tumor
  2. Xu, X.; Hou, Y.; Yin, X. Y.; Bao, L.; Tang, A. F.; Song, L. T.; Li, F. Q.; Tsang, S.; Wu, K.; Wu, H. J.; He, W. M.; Zeng, L.; Xing, M. J.; Wu, R. H.; Jiang, H.; Liu, X.; Cao, D. D.; Guo, G. W.; Hu, X. D.; Gui, Y. T.; Li, Z. S.; Xie, W. Y.; Sun, X. J.; Shi, M.; Cai, Z. M.; Wang, B.; Zhong, M. M.; Li, J. X.; Lu, Z. H.; Gu, N.; Zhang, X. Q.; Goodman, L.; Bolund, L.; Wang, J.; Yang, H. M.; Kristiansen, K.; Dean, M.; Li, Y. R.
  3. Cell. 2012, Mar; 148(5): 886-895.
  1. 15.   CHEK2 genomic and proteomic analyses reveal genetic inactivation or endogenous activation across the 60 cell lines of the US National Cancer Institute
  2. Zoppoli, G.; Solier, S.; Reinhold, W. C.; Liu, H.; Connelly, J. W.; Monks, A.; Shoemaker, R. H.; Abaan, O. D.; Davis, S. R.; Meltzer, P. S.; Doroshow, J. H.; Pommier, Y.
  3. Oncogene. 2012, Jan; 31(4): 403-418.
  1. 16.   Preclinical therapeutic response of residual metastatic disease is distinct from its primary tumor of origin
  2. Day, C. P.; Carter, J.; Bonomi, C.; Hollingshead, M.; Merlino, G.
  3. International Journal of Cancer. 2012, Jan; 130(1): 190-199.
  1. 17.   A Flexible Bayesian Model for Studying Gene-Environment Interaction
  2. Yu, K.; Wacholder, S.; Wheeler, W.; Wang, Z. M.; Caporaso, N.; Landi, M. T.; Liang, F. M.
  3. Plos Genetics. 2012, Jan; 8(1):
  1. 18.   Molecular profiling of the human nasal epithelium: A proteomics approach
  2. Simoes, T.; Charro, N.; Blonder, J.; Faria, D.; Couto, F. M.; Chan, K. C.; Waybright, T.; Isaaq, H. J.; Veenstra, T. D.; Penque, D.
  3. Journal of Proteomics. 2011, Dec; 75(1): 56-69.
  1. 19.   Non-coding rRNA-mediated preferential killing in cancer cells is enhanced by suppression of autophagy in non-transformed counterpart
  2. Hwang, C. J.; Fields, J. R.; Shiao, Y. H.
  3. Cell Death & Disease. 2011, Dec; 2
  1. 20.   Supplementation with alpha-Tocopherol or beta-Carotene Reduces Serum Concentrations of Vascular Endothelial Growth Factor-D, but Not -A or -C, in Male Smokers
  2. Mondu, A. M.; Rager, H. C.; Kopp, W.; Virtamo, J.; Albanes, D.
  3. Journal of Nutrition. 2011, Nov; 141(11): 2030-2034.
  1. 21.   Activation of the c-Jun N-terminal Kinase/Activating Transcription Factor 3 (ATF3) Pathway Characterizes Effective Arylated Diazeniumdiolate-Based Nitric Oxide-Releasing Anticancer Prodrugs
  2. Maciag, A. E.; Nandurdikar, R. S.; Hong, S. Y.; Chakrapan, H.; Diwan, B.; Morris, N. L.; Shami, P. J.; Shiao, Y. H.; Anderson, L. M.; Keefer, L. K.; Saavedra, J. E.
  3. Journal of Medicinal Chemistry. 2011, Nov; 54(22): 7751-7758.
  1. 22.   Identification of Potential Protein Targets of Isothiocyanates by Proteomics
  2. Mi, L. X.; Hood, B. L.; Stewart, N. A.; Xiao, Z.; Govind, S.; Wang, X. T.; Conrads, T. P.; Veenstra, T. D.; Chung, F. L.
  3. Chemical Research in Toxicology. 2011, Oct; 24(10): 1735-1743.
  1. 23.   The B-Raf Status of Tumor Cells May Be a Significant Determinant of Both Antitumor and Anti-Angiogenic Effects of Pazopanib in Xenograft Tumor Models
  2. Gril, B.; Palmieri, D.; Qian, Y.; Anwar, T.; Ileva, L.; Bernardo, M.; Choyke, P.; Liewehr, D. J.; Steinberg, S. M.; Steeg, P. S.
  3. Plos One. 2011, Oct; 6(10): 11.
  1. 24.   Synthesis and Biological Activities of (R)- and (S)-N-(4-Methoxyphenyl)-N,2,6-trimethyl-6,7-dihydro-5H-cyclopenta[d]pyri midin-4-aminium Chloride as Potent Cytotoxic Antitubulin Agents
  2. Ganglee, A.; Zhao, Y.; Hamel, E.; Westbrook, C.; Mooberry, S. L.
  3. Journal of Medicinal Chemistry. 2011, Sep; 54(17): 6151-6155.
  1. 25.   Pharmacogenomics and cancer stem cells: a changing landscape?
  2. Crea, F.; Duhagon, M. A.; Farrar, W. L.; Danesi, R.
  3. Trends in Pharmacological Sciences. 2011, Aug; 32(8): 487-494.
NCI at Frederick

You are leaving a government website.

This external link provides additional information that is consistent with the intended purpose of this site. The government cannot attest to the accuracy of a non-federal site.

Linking to a non-federal site does not constitute an endorsement by this institution or any of its employees of the sponsors or the information and products presented on the site. You will be subject to the destination site's privacy policy when you follow the link.

ContinueCancel